Patents Represented by Attorney, Agent or Law Firm Roger S. Benjamin
  • Heterocycle substituted diphenyl leukotriene antagonists
    Patent number: 6797723
    Abstract: The invention relates to novel heterocycle substituted diphenyl leukotriene B4 (LTB4) antagonists, to compositions containing such compounds, and to methods of using such compounds for treatment of inflammatory diseases.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: September 28, 2004
    Assignee: Eli Lilly and Company
    Inventors: Jason Scott Sawyer, Douglas Wade Beight, Edward C R Smith, William Thomas McMillen
  • Indolizine SPLA2inhibitors
    Patent number: 6645976
    Abstract: A class of novel indolizine-1-functional compounds and indolizine-3-functional compounds is disclosed together with the use of such indolizine compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are indolizine-1-acetamides, indolizine-1-acetic acid hydrazides, indolizine-1-glyoxylamides, indolizine-3-acetamides, indolizine-3-acetic acid hydraxides, and indolizine-3-glyoxylasides.
    Type: Grant
    Filed: April 28, 1997
    Date of Patent: November 11, 2003
    Assignees: Eli Lilly and Company, Shiongi and Company, Ltd.
    Inventors: Robert D. Dillard, Sanji Hagishita, Mitsuaki Ohtani
  • Method for treatment of non-rheumatoid arthritis
    Patent number: 6610728
    Abstract: A method is disclosed for the treatment of non-rheumatoid arthritis by administering to a mammal in need thereof a therapeutically effective amount of an sPLA2 inhibitor.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: August 26, 2003
    Assignee: Eli Lilly and Company
    Inventor: William Louis Macias
  • Indole sPLA2 inhibitors
    Patent number: 6608099
    Abstract: A class of novel acylsulfonamide substituted indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: August 19, 2003
    Assignee: Eli Lilly and Company
    Inventors: Edward David Mihelich, Michael LeRoy Phillips, Alan M Warshawsky
  • Method for the treatment of cystic fibrosis
    Patent number: 6576654
    Abstract: A method is disclosed for the treatment of cystic fibrosis by administering to a human in need thereof a therapeutically effective amount of an sPLA2 inhibitor, such as a 1H-indole-3-glyoxylamide.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: June 10, 2003
    Assignee: Eli Lilly and Company
    Inventor: William Louis Macias
  • Treatment for alzheimer's disease
    Patent number: 6514984
    Abstract: A method is disclosed for the prevention and treatment of Alzheimer's disease by administering to a human in need thereof an effective amount of a substituted tricyclic sPLA2 inhibitor.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: February 4, 2003
    Assignee: Eli Lilly and Company
    Inventor: August Masaru Watanabe
  • Process for preparing N-benzyl indoles
    Patent number: 6509476
    Abstract: This invention relates to a method of making N-benzyl indoles, and to intermediates for use in the method, and to certain substantially optically pure N-benzyl indoles obtained by the method.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: January 21, 2003
    Assignees: The University of East Anglia, Eli Lilly and Company
    Inventors: Nicholas James Bach, Stephen Richard Baker, Jeremy Gilmore, Russell Andrew Lewthwaite, Alexander McKillop, Jason Scott Sawyer, George Richard Stephenson, Michael William John Urquhart
  • Indole sPLA2 inhibitors
    Patent number: 6451839
    Abstract: A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: September 17, 2002
    Assignee: Eli Lilly and Company
    Inventors: Nicholas James Bach, Robert Delane Dillard, Susan Elizabeth Draheim, Edward David Mihelich, Tulio Suarez
  • Treatment for alzheimer's disease
    Patent number: 6436983
    Abstract: This invention is a method of treating a mammal, including a human, susceptible to having Alzheimer's disease, to prevent or delay the onset of Alzheimer's disease; said method comprising administering to said mammal a prophylactically effective amount of 1H-indole-3-glycoxyamide sPLA2 inhibitor or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: August 20, 2002
    Assignee: Eli Lilly and Company
    Inventor: August M Watanabe
  • 1H-indole-3-glyoxylamide sPLA2 inhibitors
    Patent number: 6433001
    Abstract: A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: November 16, 2000
    Date of Patent: August 13, 2002
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim
  • Oxime amide indole type sPLA2 inhibitors
    Patent number: 6391908
    Abstract: A class of novel oxime indoles is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 21, 2002
    Assignee: Eli Lilly and Company
    Inventors: Nicholas James Bach, Richard Waltz Harper, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett
  • Bicyclic sPLA2 inhibitors
    Patent number: 6384041
    Abstract: The compounds are of the class of pyrrolo[2,3-d]pyrimidines useful for inhibiting sPLA2 mediated release of fatty acids for treatment of diseases such as septic shock.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: May 7, 2002
    Assignee: Eli Lilly and Company
    Inventors: Darrell Robert Hutchison, Michael John Martinelli, Thomas Michael Wilson
  • SPLA2 inhibitor compounds for treatment of disease
    Patent number: 6340699
    Abstract: The present invention is directed to compounds for treating inflammatory bowel disease. More specifically, the present invention is directed to 1H-indole-3-glyoxyamide compounds a sPLA2 inhibitors for treating inflammatory bowel disease.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: January 22, 2002
    Assignee: Eli Lilly and Company
    Inventor: William Louis Macias
  • Method of treating gout with certain indole compounds
    Patent number: 6303610
    Abstract: This invention relates to a method of treating gout with certain indole compounds and other aromatic compounds.
    Type: Grant
    Filed: March 6, 2000
    Date of Patent: October 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Douglas W Johnson, John M Morin, Jr., Jason S Sawyer, Robert T Shuman
  • N,N-diethylglycolamido ester prodrugs of indole sPLA2 inhibitors
    Patent number: 6274616
    Abstract: The compound, ((3-(2-amino-1,2-dioxoethyl)-1-((1,1′-biphenyl-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid N,N-diethylglycolamido ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: March 29, 2000
    Date of Patent: August 14, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael L Denney, John M Morin, Jr., Daniel J Sall, Jason S Sawyer
  • sPLA2 inhibitor ester
    Patent number: 6274578
    Abstract: The compound, ((3(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid N-morpholino ester, is disclosed together with its use as a highly bioavailable indole sPLA2 inhibitor compound.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: August 14, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael Lyle Denney, John Michael Morin, Daniel Jon Sall, Jason Scott Sawyer
  • 1H-indole-3-acetamide sPLA2 inhibitors
    Patent number: 6252084
    Abstract: A class of novel 1H-indole-3-acetamides is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: June 26, 2001
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim, Robert B. Hermann, Richard W. Schevitz
  • Indene-1-acetamide sPLA2 inhibitors
    Patent number: 6214876
    Abstract: Indene-1-acetamide compounds of the general formula (I) below; inhibit sPLA2 mediated release of fatty acids and are useful for treatment of conditions such as septic shock.
    Type: Grant
    Filed: July 21, 1994
    Date of Patent: April 10, 2001
    Assignees: Eli Lilly and Company, Shionogi & Company, Ltd.
    Inventors: Robert D. Dillard, Sanji Hagishita, Mitsuaki Ohtani
  • Morpholino-N-ethyl ester prodrugs of indole sPLA2 inhibitors
    Patent number: 6177426
    Abstract: The compound, ((3(2-amino-1,2-dioxoethyl)-1-((1,1′-biphenyl)-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid morpholino-ethyl ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: March 29, 2000
    Date of Patent: January 23, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael L Denney, John M Morin, Daniel J Sall, Jason S Sawyer
  • 1H-indole-3-glyoxylamide sPLA2 inhibitors
    Patent number: 6175021
    Abstract: A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: January 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim